DIA Biosimilars 2013

ISTA Pharmaceuticals

Omeros appoints Mitro as vice president, sales and marketing

Tuesday, December 4, 2012 08:00 AM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company focused on products targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed Thomas A. Mitro as vice president of sales and marketing.

More... »

Cenduit: Now with Patient Reminders

ISTA stockholders approve acquisition by Bausch + Lomb

Wednesday, June 6, 2012 10:05 AM

At a special meeting on Tuesday, June 5, ISTA Pharmaceuticals stockholders voted to approve the merger of ISTA and Bausch & Lomb.

More... »

CRF Health – eCOA Forum

Bausch + Lomb acquires ISTA Pharmaceuticals

Wednesday, March 28, 2012 10:47 AM

Bausch + Lomb, the global eye health company, has signed a definitive agreement to buy ISTA Pharmaceuticals for $9.10 per share in cash, or an approximate total of $500 million. The transaction was unanimously approved by the boards of directors of both companies and is expected to close in the second quarter of 2012.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs